StockNews.AISignal intelligence
Company intelligence

BAX

Baxter International Inc. · NYSE · Healthcare

Price$25.81+0.27% · +$0.07
Market cap13.35BEquity value
P / E12.4Trailing ratio
Volume4.49MLatest session
Market data

BAX price chart

TradingView
Related signals
1 min delayed

Browse public BAX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

BAXOct 29, 2026-4.15% since signal

Baxter Beats, Lifts 2026 Guidance but Faces 2027 Margin Headwinds

Baxter International reported a solid Q3 with an EPS beat and raised full-year 2026 guidance, led by strength in Advanced Surgery and Infusion Systems. The company will discontinue cephalosporin production at Round Lake to simplify operations and address FDA considerations while preserving supply continuity. Management warned of 2027 margin headwinds but cited cost-saving opportunities, suggesting near-term upside on robust demand but longer-term margin risk.

View signal analysis
BAXJul 30, 2026-5.53% since signal

Baxter Surges on Q2 Beat and Raised 2026 Guidance

Baxter beat Q2 expectations with adjusted EPS of 0.54 and revenue of $2.96 billion, driven by Medical Products growth and tariff refunds. The company raised full-year 2026 guidance for both sales and earnings and expects margin expansion in the back half due to volumes and cost actions. The stock jumped about 11%, reflecting investor confidence in the turnaround trajectory.

View signal analysis
Research

Company intelligence